FTSE 100 pharma giants GSK and Astrazeneca may have escaped the worst of US President Donald Trump’s tariffs, according to a ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

Pharmaceutical goods appear to be exempt from higher-rate tariffs introduced by President Trump in his 'Liberation Day' ...

Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

GSK PLC closed 21.39% short of its 52-week high of £18.24, which the company reached on May 16th.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Sanofi hires former GSK development head Chris Corsico as global R&D head, replacing Dietmar Berger who left for Gilead. Move aligns with €2B R&D investment strategy.

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

Shares of GSK plc (LON:GSK – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. One research ...

GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to ...